CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenue	$ 1,136	$ 3,699	$ 3,291	$ 4,627
Operating expenses
Research and development	8,108	7,048	23,836	31,794
General and administrative	6,280	9,082	20,372	26,839
Total operating expenses	14,388	16,130	44,208	58,633
Loss from operations	(13,252)	(12,431)	(40,917)	(54,006)
Other income (expense), net	282	714	743	1,898
Net loss	(12,970)	(11,717)	(40,174)	(52,108)
Other comprehensive income (loss)
Foreign currency translation adjustment	(5)	5	3	2
Unrealized gain (loss) on marketable securities	0	0	0	(1)
Comprehensive loss	(12,975)	(11,712)	(40,171)	(52,107)
Common Stock
Other comprehensive income (loss)
Net loss attributable to shareholders - basic	(12,970)	(11,717)	(40,128)	(52,108)
Net loss attributable to shareholders - diluted	$ (12,970)	$ (11,717)	$ (40,128)	$ (52,108)
Weighted shares used in calculating net loss per share - basic (in shares)	278,171,593	256,492,558	264,303,494	240,222,667
Weighted shares used in calculating net loss per share - diluted (in shares)	278,171,593	256,492,558	264,303,494	240,222,667
Net loss per share attributable to shareholders - basic (in USD per share)	$ (0.05)	$ (0.05)	$ (0.15)	$ (0.22)
Net loss per share attributable to shareholders - diluted (in USD per share)	$ (0.05)	$ (0.05)	$ (0.15)	$ (0.22)
Series B Convertible Preferred Stock
Other comprehensive income (loss)
Net loss attributable to shareholders - basic	$ 0	$ 0	$ (46)	$ 0
Net loss attributable to shareholders - diluted	$ 0	$ 0	$ (46)	$ 0
Weighted shares used in calculating net loss per share - basic (in shares)	0	0	54,745	0
Weighted shares used in calculating net loss per share - diluted (in shares)	0	0	54,745	0
Net loss per share attributable to shareholders - basic (in USD per share)	$ 0	$ 0	$ (0.84)	$ 0
Net loss per share attributable to shareholders - diluted (in USD per share)	$ 0	$ 0	$ (0.84)	$ 0
Collaborative Arrangements
Total revenue	$ 1,136	$ 3,699	$ 3,291	$ 4,627
Operating expenses
Research and development			$ 900	$ 3,500